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sensitizing EGFR mutations.1 Possible
explanations for the noncross resis-
tance of EGFR tyrosine kinase to ge-
fitinib and erlotinib include a true
qualitative difference between the two
molecules, differential sensitivity of ge-
fitinib and erlotinib to known acquired
secondary mutations like T790M pos-
sibly conferred by other unknown mu-
tations,4 or yet unknown mechanisms of
acquired resistance which may entail
nonoverlapping susceptibilities of ge-
fitinib and erlotinib. The clinical ben-
efit seen with the readministration of
gefitinib in our patient could also be
explained by the loss of acquired-re-
sistance after a significant “TKI-free
interval”.2 Conventional chemother-
apy given during the TKI-free interval
could also have resulted in reduction
of TKI-resistant clones, leaving TKI-
sensitive ones susceptible to subse-
quent rechallenge with the same drug.2
Applying the principles of clinical
noncross resistance between gefitinib and
erlotinib,1,3–5 as well as the loss of ac-
quired-resistance after a TKI-free in-
terval,2 we obtained repeated responses
and a prolonged survival in this patient
by an unprecedented alternating use of
gefitinib and erlotinib.
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Docetaxel as Second
Line Therapy in
Advanced Non-small
Cell Lung Cancer—The
Dose and Combination
May Matter!
To the Editor:
We read with interest the study by
Sekine and coworkers1 wherein the au-
thors have assessed the efficacy of do-
cetaxel as second line therapy in advanced
nonsmall cell lung cancer (NSCLC). This
study, reinforces the usefulness of do-
cetaxel monotherapy after failure of first
line chemotherapy in advanced NSCLC.
There are certain issues related to the cur-
rent study, however, which need further
clarification.
Firstly, docetaxel was adminis-
tered at the dose of 60 mg/m2 every 3
weeks leading to a dose intensity of 20
mg/m2/wk. Previous randomized trials
that have assessed the efficacy of do-
cetaxel as second line therapy in NSCLC
have used dose regimens of either 100
mg/m2 or 75 mg/m2 every 3 weeks which
have thus meant dose intensities of 33 and
25 mg/m2/wk, respectively.2–5 The use of
docetaxel at dose of 100 mg/m2 was asso-
ciated with significant hematological and
nonhematological toxicity whereas its us-
age at 75 mg/m2 was well tolerated. Infact,
even in other solid tumors, wherein do-
cetaxel has been administered as 3 weekly
cycles, the dose that has been most fre-
quently used and is currently recom-
mended has been 75 mg/m2.6
Secondly, statistically significant
differences existed between the pacli-
taxel (P) and nonpaclitaxel (NP) groups
with respect to the percentage of pa-
tients with stage III disease (26.8 versus
51.0%; p 0.002) and the percentage of
patients who had received radiation
therapy (0 versus 29.0%; p  0.001).
Moreover, an individual patient
data meta-analysis involving 2968 pa-
tients from nine randomized trials has
shown that the objective response rates
are higher for patients treated with cis-
platin than for those treated with carbo-
platin [30 versus 24%; odds ratio
{OR}  1.37, 95% confidence interval
{CI}  1.16–1.61; p  0.001].7 Infact,
carboplatin-based chemotherapy was as-
sociated with a statistically significant
increase in mortality among patients
with nonsquamous histology (hazards
ratio  1.12; 95% CI  1.01–1.23) and
among those treated with third genera-
tion chemotherapeutic agents (docetaxel,
paclitaxel and gemcitabine) (hazards ra-
tio  1.11; 95% CI  1.01–1.21). On the
other hand, cisplatin-based chemotherapy
is associated with a higher incidence of
grade 3/4 nausea and vomiting and neph-
rotoxicity (OR  0.39; 95% CI  0.30–
0.52; p  0.00001 and OR  0.31;
95%CI, 0.17–0.56; p  0.0001).8 In the
current study, cisplatin had been adminis-
tered in 72% of patients in the NP group
whereas all the patients in the P group had
received carboplatin.
It is therefore possible that use of
a lesser dose intensity of docetaxel, in-
herent differences in the efficacy and
toxicity profile of individual platinum
compounds as well as differences in the
baseline characteristics of patients in the
P and NP groups could have acted as
potentially confounding factors in the
current study. These factors could have
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thus influenced the results including
those assessed (overall survival) and not
assessed (disease free survival and time
to progression). Future studies on the
efficacy of docetaxel as a second line agent
should serve to address issues like the
optimal dose regimen and intensity as well
as adjust for potential confounders.
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Reply: Higher Intensity
Does Not Necessary
Yield Better Survival in
Second-Line
Chemotherapy for
NSCLC
To the Editor:
We would like to thank Singh et al.
for suggesting that the dose of docetaxel
and previous treatment modality may have
an impact on second-line therapy in non-
small cell lung cancer (NSCLC). Herein,
we discuss the dose of docetaxel and the
influence of previous chemotherapy in re-
lation to second-line treatment of NSCLC.
In second-line chemotherapy for
NSCLC, whether a higher dose of an an-
ticancer agent would inevitably yield a
longer survival is open to question. In a
study comparing docetaxel 100 mg/m2,
docetaxel 75 mg/m2 and best supportive
care, the overall survivals were 5.9, 7.5,
and 7.0 months, respectively.1 Docetaxel
100 mg/m2 was also found to be inferior
to docetaxel 75 mg/m2 in terms of the
1-year survival rate in another phase III
study.2 A similar tendency was also ob-
served for another agent in the second-line
setting; pemetrexed 500 mg/m2 and 900
mg/m2 were compared, and the overall
median survivals were 6.7 and 6.9 months,
respectively, and the hazard ratio was
1.013 (95% confidence interval, 0.837–
1.226).3 Even the response rate in the 900
mg/m2 arm did not exceed that in the 500
mg/m2. Thus, finding the optimal dose of
docetaxel or other agents for second-line
chemotherapy may be an intriguing issue.4
Meanwhile, docetaxel 60 mg/m2
is the standard therapeutic dose in Japan,
since a Japanese phase I trial determined the
maximum tolerated dose to be 70 mg/m2.5
Even though this dose of docetaxel is
lesser than that used in other countries,
this may be the optimal dose for Japa-
nese. In a phase II study of docetaxel for
previously untreated NSCLC conducted
in Japan, the response rate to docetaxel
60 mg/m2 was 19%, no less than that to
the higher doses used in other coun-
tries.6 A retrospective study evaluating
docetaxel 60 mg/m2 for previously
treated NSCLC also showed a response
rate of 18.5%, comparable with that
reported for higher doses.7 This differ-
ence in the dose requirement in Japa-
nese may be attributed to ethnic dif-
ferences between the Japanese and
other populations, but the issue re-
mains under debate.
The previously employed treat-
ment modality differed between those
who had received a combination of car-
boplatin and paclitaxel (group P) and
those who had received a combination
of a platinum and an agent other than
paclitaxel [group nonpaclitaxel (NP)] in
our study. We consider, however, that
this difference had only a small impact
on our study results, for three reasons.
Firstly, all the patients in our study had
metastatic disease at the time of recur-
rence and start of docetaxel therapy.
Secondly, although 29% of patients in
group NP had received radiotherapy, the
response rate to the previous treatment
in group NP was the same as that in
group P (45.0 versus 44.9%, respec-
tively). In general, the response rate to
chemoradiotherapy is higher than that to
chemotherapy alone. This difference
may have disappeared in our study,
probably because we only recruited pa-
tients who developed recurrence after
chemoradiotherapy. Finally, no previous
studies of second-line chemotherapy for
NSCLC have dealt with these issues.
Even though multiple modalities may
have been used in previous treatment,
we can only evaluate the integrated re-
sult of the treatment. It is impossible to
distinguish between the efficacy of che-
motherapy and radiotherapy if both are
undertaken simultaneously.
In conclusion, further investigation
of the optimal dose of chemotherapeutic
agents for second-line chemotherapy of
NSCLC is warranted. The efficacy of pre-
vious chemotherapy, whether or not ad-
ministered in combination with radiother-
apy, is a useful reference for subsequent
docetaxel therapy.
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